Tech giant Apple (AAPL) unveiled the highly-anticipated iPhone Air at its annual product launch event in Cupertino, California on Tuesday. The company described the new phone as "impossibly thin" at 5 ...

A onetime bull now feels the stock is only a hold. Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

Dow Jones futures rose modestly early Monday, along with S&P 500 futures and Nasdaq futures. Bitcoin rose vs. Friday but was off Sunday highs. The stock market suffered significant losses this past ...

It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings season. Major banks exceeded expectations, ...

NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, ...

Novo Nordisk's latest quarterly update disappointed investors -- again. But the company has a lot going on behind the scenes that affects its outlook. Between a strong pipeline and a reasonable ...

Novo Nordisk has both internal research and external alliances pursuing new drugs that could shape the next generation of metabolic medicines. The pharmaceutical giant’s latest move is a partnership ...

Pfizer has launched a two-pronged litigation effort to stop Novo Nordisk from acquiring a weight loss drug company, filing a breach of contract suit in the Court of Chancery on Friday and an antitrust ...